Study of price variation analysis of fluoroquinolones eye drops manufactured by various pharmaceutical companies in India

Dinesh Prasad Sinha, Bhuwaneshwari Sinha, Santosh Kumar, Akash Chandra


Background: Fluoroquinolone eye drops is being prescribed by Opthalmologist in many ocular diseases as conjunctivitis, keratitis, bacterial corneal ulcers etc in more and more amount. There are many brands of fluoroquinolones drugs available in Indian market. Costly drugs can lead to economic burden on patients. Modifications in pharmaceutical policy are required, and prices of the drug should be controlled in effective way for all the drugs. Hence this study was done to assess the cost variation of fluoroquinolones opthalmic solutions available in Indian market.

Methods: The maximum and minimum price of each brand of the drug in INR was noted by using CIMS January to April 2020 edition and Drug Today April to June 2020 volume 1. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of each eye drop was calculated. At last the cost ratio and percentage cost variation of various brands was compared.

Results: Percentage variation in cost for fluoroquinolones eye preparations marketed in India was found to be Eye drop Ciprofloxacin (0.3%) of 5 ml:210.39, Eye drop Ciprofloxacin (0.3%) of 10 ml:162, Eye drop Gatifloxacin (0.3%) of 5 ml:156, Eye drop Moxifloxacin (0.5%) of 5 ml:196.95, Eye drop Ofloxacin (0.3%) of 5 ml:245.16, Eye drop Ofloxacin (0.3%) of 10 ml:62.5, Eye drop Norfloxacin (0.3%) of 5 ml:120.68, Eye drop Sparfloxacin (0.3%):8.31, Eye drop Lomefloxacin (0.3%):16.17.

Conclusions: There is a wide difference in the cost of different brands of fluoroquinolones eye preparations available in India. The clinicians prescribing these drugs should be aware of these variations in cost to reduce the cost of drug therapy.


Fluoroquinolones, Percentage cost variation, Keratitis, Bacterial corneal ulcer, Conjunctivitis

Full Text:



Andriole VT. The Quinolones. Academic Press, 1989.

Andersson MI, MacGowan AP. Development of the quinolones". Journal of Antimicrobial Chemotherapy. 2003;51(S1):1-11.

Heeb S, Fletcher MP, Chhabra SR, Diggle SP, Williams P, Cámara M. Quinolones: from antibiotics to autoinducers." FEMS Microbiology Reviews. 2011;35(2):247-74.

Liu H, Mulholland SG. Appropriate antibiotic treatment of genitourinary infections in hospitalized patients". American Journal of Medicine. 2005;7A(7):14S-20S.

Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Journal of Respiratory and Critical Care Medicine. 171(4):388-416.

Elsea SH, Osheroff N, Nitiss JL. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast." J Biol Chem. 1992;267(19):13150-3.

Stephenson AL, Wu W, Cortes D, Rochon PA. Tendon Injury and Fluoroquinolone Use: A Systematic Review". Drug safety. 2013;36(9):709-21.

Galatti L, Giustini SE, Sessa A. Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy". Pharmacological Research. 2005;51(3):211-6.

Heidelbaugh JJ, Holmstrom H. The perils of prescribing fluoroquinolones". The Journal of Family Practice. 2013;62(4):191-7.

AAO Cornea/External Disease PPP Panel, Hoskins Center for Quality Eye Care. Conjunctivitis PPP. ONE Network.. 2013. Accessed on 20th December, 2020.

Thomas M. Rational drug use and essential drug concept. In: A Text book of Clinical Pharmacy Practice. Parthasarthi G, Hasen K (Editors). 1st Ed. Himayatnagar, Hyderabad: Orient Longman. 2004;723.

Creese A, Kotwani A, Kutzin J, Pillay A. Evaluating pharmaceuticals for health policy in low and middle –income country settings. In: Evaluating Pharmaceuticals for Health policy and reimburssment. Freemantle N, Hills, eds. Massachusetts, USA: B lackwell Publication;(in collaboration with WHO Geneva). 2004;227-43.

Mahal A, Karan A, Engelgau M. The Economic Implications of Non-Communicable Disease for India. Washington, DC: World Bank. 2010. Implications of NCD for India .pdf. Accessed on 20th December, 2020.

Rataboli PV, Garg A. Confusing brand names: nightmare of medical profession. J Postgrad Med. 2005;51:13-6.

Drug cost control order, 2013 Government of India. http:// Last accessed on 20th December, 2020.

Vieira JL, Portal VL, Moriguchi EH. How much do we pay for a benefit? A descriptive cost analysis of the use of statins. The need for a national cost –effectiveness analysis. Arq Bras Cardiol. 2001;76(5):409-18.

Kumar L. Cost variation analysis of antimalarial drugs available in India. Int J Res Med Sci. 2017;5(9):4051-4.